What is the recommended starting dose and titration schedule of nebivolol for an adult with hypertension or heart failure with reduced ejection fraction, including adjustments for renal impairment and contraindications such as bradycardia, atrioventricular block, cardiogenic shock, and severe hepatic disease?

Nebivolol Dosing and Administration

For hypertension, start nebivolol at 5 mg once daily and titrate up to 40 mg once daily if needed; for heart failure with reduced ejection fraction, start at 1.25 mg once daily and titrate slowly to a target of 10 mg once daily. 1, 2, 3, 4, 5, 6

Hypertension Dosing

Standard Dosing

• Starting dose: 5 mg once daily 6
• Titration: Increase at 2-week intervals if further blood pressure reduction needed 6
• Maximum dose: 40 mg once daily 1, 2, 3, 4, 5, 6
• Administration: Once daily, with or without food 6

Renal Impairment Adjustments

• Severe renal impairment (CrCl <30 mL/min): Start at 2.5 mg once daily, titrate slowly 6
• Mild to moderate impairment: No dose adjustment needed 6
• Dialysis patients: Not studied; use with extreme caution 6

Hepatic Impairment Adjustments

• Moderate hepatic impairment (Child-Pugh B): Start at 2.5 mg once daily, titrate slowly 6
• Severe hepatic impairment: Contraindicated - nebivolol exposure increases 10-fold and clearance decreases 86% 6

Heart Failure with Reduced Ejection Fraction (HFrEF)

Initiation Protocol

Nebivolol is recommended for HFrEF patients (LVEF ≤40%) in NYHA class II-IV who are clinically stable, alongside ACE inhibitors/ARBs and diuretics. 7, 8

• Starting dose: 1.25 mg once daily 9, 10
• Target dose: 10 mg once daily 9, 10, 11
• Titration schedule: Double dose every 1-2 weeks if tolerated 9, 10
• Typical progression: 1.25 mg → 2.5 mg → 5 mg → 10 mg 9

Patient Selection Criteria

Initiate nebivolol in patients who:

• Have LVEF ≤40% 10
• Are on optimal ACE inhibitor or ARB therapy 9, 10
• Are clinically stable without recent decompensation 9, 10
• Are not dependent on intravenous inotropes 10
• Have no signs of marked fluid retention 9

Monitoring During Titration

At each visit (every 1-2 weeks), assess:

• Heart rate: Hold or reduce dose if <50 bpm with symptoms 9
• Blood pressure: Reduce other vasodilators first if symptomatic hypotension occurs 9
• Volume status: Increase diuretics if worsening congestion develops 9
• Renal function and electrolytes: Check 1-2 weeks after initiation and final titration 12

Absolute Contraindications

Do not use nebivolol in patients with: 6

• Severe bradycardia (HR <50 bpm with symptoms)
• Second- or third-degree AV block without pacemaker 9, 10
• Sick sinus syndrome without pacemaker 9, 10
• Cardiogenic shock 10
• Severe hepatic impairment 6
• Decompensated heart failure requiring IV inotropes 10

Special Populations

Elderly Patients

• No dose adjustment required 6
• Evidence from SENIORS trial supports efficacy in patients ≥70 years 11
• Target dose of 10 mg daily achieves optimal outcomes 11

CYP2D6 Poor Metabolizers

• No dose adjustment necessary 6
• Despite 5-fold higher Cmax and 10-fold higher AUC, clinical effects remain similar due to active metabolites 6

Critical Clinical Pearls

Avoid Abrupt Discontinuation

Never stop nebivolol suddenly - taper over 1-2 weeks to prevent rebound hypertension, angina, or myocardial infarction 1, 2, 3, 4, 5

Blood Pressure Tolerance

• Mild hypotension (SBP 90-110 mmHg) without symptoms is not a reason to withhold or reduce nebivolol 8
• Reduce other vasodilators first before adjusting beta-blocker dose 9

Hospitalized HFrEF Patients

• Continue nebivolol during hospitalization unless cardiogenic shock, marked volume overload, or need for IV inotropes 8
• Can initiate cautiously pre-discharge in stabilized patients with close 24-hour monitoring 10, 8

Drug Interactions

• Fluoxetine (CYP2D6 inhibitor): Increases nebivolol exposure 8-fold; monitor closely and reduce dose if needed 6
• Cimetidine: Increases nebivolol levels by 23%; consider dose reduction 6
• Digoxin, warfarin, diuretics, ACE inhibitors, ARBs: No significant interactions 6

Common Pitfalls to Avoid

1. Starting too high in HFrEF: Always begin at 1.25 mg, not the hypertension dose of 5 mg
2. Stopping for asymptomatic bradycardia: HR 50-60 bpm without symptoms does not require dose reduction
3. Discontinuing during mild decompensation: Increase diuretics first; maintain beta-blocker if possible
4. Using in severe hepatic disease: This is an absolute contraindication due to massive drug accumulation 6
5. Ignoring renal function: Severe renal impairment requires 50% dose reduction 6